65,437 trials
Severe Hypertriglyceridemia
Primary: Percent Change From Baseline to Week 8 in Serum Triglyceride (TG) — -57.33; -11.85 percent change from Baseline — p=<0.001
Healthy
Primary: Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration — 0; 0; 0; 0 participants
Tinnitus
Primary: Number of Participants With Changes in Blood Oxygen Level as Measured by Functional Connectivity MRI — 18 participants — p=<0.01
Anterior Cruciate Ligament Injuries
Primary: Neural Mechanisms for Injury-resistant Movement Pattern Acquisition — 0.28; 0.26; 0.26; 0.21 % BOLD Signal change
Suicide
Primary: Reach — 0.2735; 0.4045 proportion of visits
Pneumococcal Disease
Primary: Percentage of Participants With Solicited Injection-site AEs From Day 1 Through Day 5 Postvaccination in Part A — 3.9; 11.0; 50.3; 82.6 Percentage of Participants
Skin Condition · Skin Diseases · Skin Lesion
Primary: Comparative Reader Percentage Agreement — 100; 100 percentage of agreement
Alzheimer Disease · Dementia · Mild Cognitive Impairment
Primary: Change in Physical Activity of Care Recipient — 3.20; 2.76; 3.01; 2.66 days
Bladder Cancer
Primary: Change in Severity of Urinary Symptoms as Determined by the The International Prostate Symptom Score (IPSS) Questionnaire Score. — -2; -3 score on a scale
Cognitive Side Effects of Cancer Therapy · Depression · Recurrent Breast Carcinoma
Primary: AUC Change in Level of IL-6 — 5.23; 10.17 ug*hour/ml
Spinal Cord Injuries · Cardiometabolic Diseases
Primary: Aerobic Capacity Baseline — 11.6; 10 ml/kg/min
Behavior
Primary: Mood Ratings (Pos) — 1.34; 1.04; .96; .83 units on a scale
Glioblastoma
Primary: Increase of Interferon Gamma Levels — 0 Participants
Nicotine Dependence
Primary: Prolonged Abstinence: Biologically Verified Cigarette Smoking Abstinence for 6 Months — 17; 4 Participants — p=0.003
Colorectal Cancer · Colon Cancer
Primary: FIT Completion — 469; 470; 558; 381 Participants